Transplantology, Volume 6, Issue 4
2025 December - 10 articles
Cover Story: We conducted a retrospective case series of five adult lung transplant recipients (LTRs) converted to belatacept with CNI elimination between 2020 and 2023 with a median follow up of 3.49 years (IQR 16.4). Post-conversion, eGFR improved with a median change of +18 mL/min/1.73 m2 (IQR 6–34) at 12 months. Force expiratory volume in 1 s (FEV1) declined from baseline to last follow-up (median change −0.53 L). At a median of 199 days post-conversion (IQR 108–453), belatacept was discontinued in 4/5 (80%) LTR, primarily due to graft dysfunction (3/4), and CNI therapy resumed. Belatacept with complete CNI elimination in LTR resulted in a sustained improvement in renal function in this series but was accompanied by a high discontinuation rate due to worsening graft function. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.